Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Relationships, marriage, and partner abandonment among Hodgkin lymphoma survivors treated in nine EORTC-GELA Lymphoma Group trials
Published in: Leukemia and Lymphoma
Access to document
10.1080/10428194.2024.2390565
Sára Rossetti, Sidsel J. Juul, Marleen A.E. van der Kaaij, Catherine Fortpied, Paul Meijnders, Berthe M.P. Aleman, John M.M. Raemaekers, Hanneke C. Kluin‑Nelemans, Michele Spina, Christophe Fermé, Loïc Renaud, Olivier Casasnovas, Aspasia Stamatoullas, Wouter J. Plattel, Martin Hutchings, Maja V. Maraldo
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2023012531
document
Optimal treatment in patients with refractory or relapsed peripheral T-cell lymphomas (R/R T-NHLs) is unknown. In this population-based study, outcomes in R/R peripheral T-cell lymphoma not otherwise specified (PTCL NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase-positive (ALK+) and ALK-negative (ALK-) anaplastic large cell lymphoma (ALCL) were evaluated. Patients with PTCL NOS, AITL, ALK+ ALCL, and ALK- ALCL (≥18 years) diagnosed in 2014 to 2019 were identified using the Netherlands Cancer Registry. End points were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). The...
Mirian Brink, Francien Huisman, Frederik O Meeuwes, Marjolein W M van der Poel, Marie José Kersten, Mariëlle Wondergem, Lara Böhmer, F J Sherida H Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M Jansen, Arjan Diepstra, Tjeerd J F Snijders, Gerwin Huls, Joost S P Vermaat, Wouter J Plattel, Marcel Nijland
Reply to T. Vassilakopoulos et al
Published in: Journal of Clinical Oncology
Access to document
10.1200/JCO.24.00143
Massimo Federico, Wouter Plattel, Martin Hutchings, Yana Stepanishyna, Catherine Fortpied, Marc André
Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials
Published in: Journal of Cancer Survivorship
Access to document
10.1007/s11764-022-01305-w
document
Purpose: Little is known about the employment situation of long-term Hodgkin lymphoma (HL) survivors despite their young age at diagnosis and the favorable prognosis of the disease. In this cross-sectional study, we aim to describe the employment situation in a cohort of long-term HL survivors compared to the general population and investigate the associations with disease characteristics and treatment exposure. Methods: HL survivors > 25 years (n = 1961) were matched 1:25 to controls (n = 49,025) from the European Union Labour Force Survey. Individual treatment information was obtained...
Sidsel J. Juul, Sára Rossetti, Michal Kicinski, Marleen A.E. van der Kaaij, Francesco Giusti, Paul Meijnders, Berthe M.P. Aleman, John M.M. Raemaekers, Hanneke C. Kluin-Nelemans, Michele Spina, Christophe Fermé, Loïc Renaud, Olivier Casasnovas, Aspasia Stamatoullas, Marc André, Fabien Le Bras, Wouter J. Plattel, Michel Henry-Amar, Martin Hutchings, Maja V. Maraldo
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma
Published in: Journal of Clinical Oncology
Access to document
10.1200/JCO.23.01386
document
PURPOSE Female Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Studies in childhood cancer survivors have shown that doxorubicin exposure may also increase BC risk. Although doxorubicin is the cornerstone of HL chemotherapy, the association between doxorubicin and BC risk has not been examined in HL survivors treated at adult ages. METHODS We assessed BC risk in a cohort of 1,964 female 5-year HL survivors, treated at age 15-50 years in 20 Dutch hospitals...
Suzanne I.M. Neppelenbroek, Yvonne M. Geurts, Berthe M.P. Aleman, Pieternella J. Lugtenburg, Saskia E. Rademakers, Roel J. De Weijer, Maaike G.A. Schippers, Bastiaan D.P. Ta, Wouter J. Plattel, Josée M. Zijlstra, Richard W.M. Van Der Maazen, Marten R. Nijziel, Francisca Ong, Erik C. Schimmel, Eduardus F.M. Posthuma, Marie José Kersten, Lara H. Böhmer, Karin Muller, Harry R. Koene, Liane C.J. Te BoomeYavuz M. Bilgin, Eva De Jongh, Cécile P.M. Janus, Flora E. Van Leeuwen, Michael Schaapveld